Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

被引：26

作者：

Woyach, Jennifer A. ^{[1
]}

Flinn, Ian W. ^{[2
]}

Awan, Farrukh T. ^{[3
]}

Eradat, Herbert ^{[4
]}

Brander, Danielle ^{[5
]}

Tees, Michael ^{[6
]}

Parikh, Sameer A. ^{[7
]}

Phillips, Tycel J. ^{[8
]}

Ghori, Razi ^{[9
]}

Reddy, Nishitha M. ^{[9
]}

Farooqui, Mohammed Z. H. ^{[9
]}

Byrd, John C. ^{[10
]}

Stephens, Deborah M. ^{[11
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[5] Duke Univ, Duke PDC, Durham, NC USA

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Mayo Clin, Rochester, MN USA

[8] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[9] Merck & Co Inc, Rahway, NJ 07065 USA

[10] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

关键词：

D O I：

10.1182/blood-2022-163596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7004 / 7006

页数：3